The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.

Telecommunications and internet group SoftBank’s Vision Fund 2 led a $225m series D round for UK-based, artificial intelligence-equipped drug developer Exscientia yesterday.

The round also featured pharmaceutical firms Novo and Bristol-Myers Squibb in addition to Pivotal BioVenture Partners, the life sciences venture capital fund formed by property developer Nan Fung’s Life Sciences subsidiary.

The Abu Dhabi-owned Mubadala Investment Company filled out the round together with Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Laurion Capital, Hongkou Capital and funds…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn